First-In-Human Phase 1 Trial of IO-108, an Antagonist Antibody Targeting LILRB2 (ILT4) as Monotherapy and in Combination with Pembrolizumab in Advanced Solid Tumors: Dose Escalation Data

Written By Vikki Christian

Matthew H. Taylor, M.D., et al. The American Association for Cancer Research (AACR) Annual Meeting 2023. April 14–19, 2023

Vikki Christian
Previous

A Novel Bispecific LILRB4 x CD3 Antibody with Potent killing of Monocytic Acute Myeloid Leukemia Cells
Next

A Phase 1 Trial of IO-202, An Antagonist Antibody Targeting Myeloid Checkpoint LILRB4 (ILT3), in Adult Patients with Advanced Relapsed or Refractory Solid Tumors